ATRIAL FIBRILLATION AND RENAL DYSFUNCTION: CURRENT STATE OF THE PROBLEM AND THE PROSPECTS OF FURTHER STUDY
https://doi.org/10.15829/1560-4071-2016-4-eng-198-201
Abstract
The review of literature is devoted to interrelations between atrial fibrillation (AF) and kidney function. The focus is on the most probable mechanisms of renal dysfunction in patients with atrial fibrillation such as fibrosis, inflammation, neurohormonal activation. The impact of central and renal hemodynamics disorders on chronic kidney disease development in atrial fibrillation patients is under consideration. The problem of atrial fibrillation in end-stage renal disease patients also gets the authors’ attention. We identified unresolved issues and the prospects for their further research.
About the Authors
K. V. Protasov
Irkutsk State Medical Academy of Continuing Education
Russian Federation
Russian Federation
Irkutsk
V. Z. Dorzhieva
Irkutsk State Medical Academy of Continuing Education
Russian Federation
Irkutsk
Russian Federation
Irkutsk
E. A. Petuhova
NHI Road Clinical Hospital on Irkutsk-passenger station of public corporation Russian Railways
Russian Federation
Russian Federation
Irkutsk
References
1. ESC 2010 Guidelines for the management of atrial fibrillation — executive summary. Eur Heart J. 2010; 31(19): 2369-429.
2. Angaron P, Dorian P. Antiarrhythmic drugs in atrial fibrillation: do they have a future? Can J Cardiol. 2013; 29: 1158-64.
3. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005; 45 (Suppl 3):1-15329
4. McManus DD, Corteville DC, Shlipak MG, et al. Relation of kidney function and albuminuria with atrial fibrillation (from the Heart and Soul Study). Am J Cardiol. 2009; 104 (11): 1551-5.
5. Watanabe H, Watanabe T, Sasaki S, et al. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am Heart J. 2009; 158 (4): 629-36.
6. Kobalava ZhD, Kotovskaya YuV, Villeval’de SV, et al. Arterial stiffness and chronic kidney disease: causes and consequences. Ratsional’naya farmakoterapiya v kardiologii. 2014; 10 (1): 83-91. (In Russ).
7. Soliman EZ, Prineas RJ, Go AS, et al. Chronic Renal Insufficiency Cohort (CRIC) Study Group. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J. 2010; 159(6):1102-7.
8. Gendlin GE, Reznik EV, Storozhakov GI, et al. The relationship of atrial fibrillation and renal function in patients with chronic heart failure. Nefrologiya i dializ. 2010; 12 (4): 255-62. (In Russ.).
9. Liu Ping, Sui Shujian, Xu Dongling, et al. Clinical analysis of association of cystatin c and atrial fibrillation. Russian Journal of Cardiology 2014; 111(7): 17-22.
10. Čabarkapa V. Cystatin c — more than the marker of the glomerular filtration rate. Med Pregl. 2015; 68(5-6):173-9.
11. Suzuki S, Sagara K, Otsuka T, et al. Estimated glomerular filtration rate and proteinuria are associated with persistent form of atrial fibrillation: analysis in Japanese patients. J Cardiol. 2013; 61 (1): 53-7.
12. Drapkina OM, Emel’yanov AV. Atrial fibrosis is a morphological basis of atrial fibrillation. Ratsional’naya farmakoterapiya v kardiologii. 2013; 9 (4): 417-419. (In Russ.).
13. Niu H., Li Y., Li H. et al. Matrix metalloproteinase 12 modulates high-fat-diet induced glomerular fibrogenesis and inflammation in a mouse model of obesity. Sci. Rep. 2016; 29 (6): 20171.
14. Li M, Yang G, Xie B, et al. Changes in matrix metalloproteinase-9 levels during progression of atrial fibrillation. J Int Med Res. 2014; 42(1): 224-30.
15. Kalogeropoulos AS, Tsiodras S, Rigopoulos AG, et al. Novel association patterns of cardiac remodeling markers in patients with essential hypertension and atrial fibrillation. BMC Cardiovasc Disord. 2011; 28;11:77.
16. Huxley RR, Lopez FL, MacLehose RF, et al. Novel association between plasma matrix metalloproteinase-9 and risk of incident atrial fibrillation in a case-cohort study: the Atherosclerosis Risk in Communities study. PLoS One. 2013; 8(3): e59052.
17. Bobkova IN, Kozlovskaya LV, Li OA. Matrix metalloproteinases in the pathogenesis of acute and chronic kidney diseases. Nefrologiya i dializ. 2008; 10(2): 105-111. (In Russ.).
18. Bondar’ IA, Klimontov VV. The role of matrix metalloproteinases and their inhibitors in the development of renal fibrosis in the patients with diabetes mellitus. Problemy endokrinologii. 2012; 1: 39-44 (In Russ.).
19. Zhang D, Liu X, Chen X, et al. Role of the MAPKs/TGF-β1/TRAF6 signaling pathway in atrial fibrosis of patients with chronic atrial fibrillationand rheumatic mitral valve disease. Cardiology. 2014; 129(4):216-23.
20. Rosenberg MA, Maziarz M, Tan AY, et al. Circulating fibrosis biomarkers and risk of atrial fibrillation: The Cardiovascular Health Study (CHS). Am Heart J. 2014; 167(5):723-8.
21. Bobkova IN, Chebotareva NV, Kozlovskaya LV, et al. Determination of urinary excretion of monocyte chemotactic protein-1 (MCP-1) and transforming growth factor-β1 (TGF-β1) is an invasive method of assessment of tubulointerstitial fibrosis with chronic glomerulonephritis. Nefrologiya. 2006; 10(4): 49-55 (In Russ.).
22. Bukowska A, Lendeckel U, Krohn A, et al. Atrial fibrillation down-regulates renal neutral endopeptidase expression and induces profibrotic pathways in the kidney. Europace. 2008; 10: 1212-1217.
23. Barzilay JI, Bůžková P, Kizer JR, et al. Fibrosis markers, hip fracture risk, and bone density in older adults. Osteoporos Int. 2015 Aug 13. [Epub ahead of print].
24. Kawamura M, Munetsugu Y, Kawasaki S, et al. Type III procollagen-N-peptide as a predictor of persistent atrial fibrillation recurrence after cardioversion. Europace. 2012; 14(12): 1719-25.
25. Ix J.H., Biggs M.L., Mukamal K. et al. Urine Collagen Fragments and CKD Progression The Cardiovascular Health Study. J Am Soc Nephrol. 2015; pii: ASN.2014070696. [Epub ahead of print].
26. Harada M, Van Wagoner DR, Nattel S. Role of inflammation in atrial fibrillation pathophysiology and management. Circ J. 2015; 79(3):495-502.
27. Grigoryan SV, Adamyan KG, Azapertyan LG. The role of inflammatory markers in atrial fibrillation: a review Kardiovaskulyarnaya terapiya i profilaktika. 2012; 11(5): 74-8 (In Russ.).
28. Dedkova AA, Suslova TE, Kologrivova IV, et al. Proinflammatory cytokines and cardiomyocyte autoantibodies in patients with paroxymal supraventricular tachycardias. Sibirskii meditsinskii zhurnal (g. Tomsk). 2010; 25(3): 16-9 (In Russ.).
29. Borowiec A, Kontny E, Smolis-Bąk E, et al. Prospective assessment of cytokine IL-15 activity in patients with refractory atrial fibrillation episodes. Cytokine. 2015; 74(1): 164-70.
30. Alegret JM, Aragones GL. The relevance of the association between inflammation and atrial fibrillation. Eur J Clin Invest. 2013; 43: 324-31.
31. Fu Shihui, Tao Luo, Ye Ping et al. Different types of atrial fibrillation, Renal function and mortality in elderly Chinese Patients with coronary artery disease. Clin Interv Aging. 2014; 9: 301-8.
32. Dmitriev VA, Oshchepkova EV, Titov VN. C-reactive protein and arterial hypertension: are they related? Ter. arkhiv. 2006; 5: 86-9 (In Russ.).
33. Lee BT, Ahmed FA, Hamm LL, et al. Association of C-reactive protein, tumor necrosis factor-alpha, and interleukin-6 with chronic kidney disease. BMC Nephrol. 2015; 16:77.
34. Iravanian S, Dudley SC. The Renin–Angiotensin–Aldosterone System (RAAS) and Cardiac Arrhythmias. Heart Rhythm. 2008; 5(6 Suppl. 1): 12–17.
35. Lévy S. Drug Insight: angiotensin-converting-enzyme inhibitors and atrial fibrillation — indications and contraindications. Nat. Clin. Pract. Cardiovasc. Med. 2006; 3 (4): 220-5.
36. Buglioni A, Cannone V, Sangaralingham SJ, et al. Aldosterone Predicts Cardiovascular, Renal, and Metabolic Disease in the General Community: A 4-Year Follow-Up. J Am Heart Assoc. 2015; 4 (12). pii: e002505.
37. Rüster C, Wolf G. The role of the renin-angiotensin-aldosterone system in obesity-related renal diseases. Semin Nephrol. 201333(1): 44-53.
38. Paravicini TM, Touyz RM. NADPHoxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. DiabetesCare. 2008; 31(Suppl 2): 170-80.
39. Chinushi M, Izumi D, Iijima K, et al. Antiarrhythmic vs. pro-arrhythmic effects depending on the intensity of adrenergic stimulation in a canine anthopleurin-A model of type-3 long QT syndrome. Europace. 2008; 10 (2):249-55.
40. Palatini P., Dorigatti F., Saladini F. et al. Factors associated with glomerular hyperfiltration in the early stage of hypertension. Am J Hypertens. 2012; 25 (9): 1011-6.
41. Agrawal S, Agrawal N, Garg J, et al. Heart failure and chronic kidney disease: should we use spironolactone? Am J Med Sci. 2015; 350 (2): 147-51.
42. Tareeva IE. Nefrologiya. M.: Meditsina; 2000 (In Russ.).
43. Yiin GS, Howard DP, Paul NL, et al. Recent time trends in incidence, outcome and premorbid treatment of atrial fibrillation-related stroke and other embolic vascular events: a population-based study. J Neurol. Neurosurg. Psychiatry. 2015; pii: jnnp-2015-311947. [Epub ahead of print]
44. Camm AJ. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation; an update of the 2010 ESC Guidelines for the management of atrial fibrillation — developed with the special contribution of the European Heart Rhythm Association Europace. 2012; 14 (10): 1385-413.
45. Makaritsis KP, Liakopoulos V, Leivaditis K, et al. Adaptation of renal function in heart failure. Ren. Fail. 2006; 28(7): 527–35.
46. American College of Cardiology Foundation; American Heart Association; European Society of Cardiology; Heart Rhythm Society, Wann L.S., Curtis A.B., Ellenbogen K.A. et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 CCF/AHA/HRSrecommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation 2013; 127(18):1916-26.
47. Frea S, Pidello S, Canavosio FG, et al. Clinical assessment of hypoperfusion in acute heart failure — evergreen or antique? Circ J. 2015; 79(2):398-405.
48. Atar I, Kona D, Aзikel S, et al. Frequency of atrial fibrillation and factors related to its development in dialysis patients. Int J Cardiol. 2006; 106(1): 47-51.
49. Narula AS, Jha V, Bali HK, et al. Cardiac arrhythmias and silent myocardial ischemia during hemodialysis. Ren. Fail. 2000; 22(3): 355-68.
50. Shih CJ, Ou SM, Chao PW, et al. Risks of Death and Stroke in Patients Undergoing Hemodialysis With New-Onset Atrial Fibrillation: A Competing-Risk Analysis of a Nationwide Cohort. Circulation. 2016; 133 (3): 265-72.
51. Shen JI, Turakhia MP, Winkelmayer WC. Anticoagulation for atrial fibrillation in patients on dialysis: are the benefits worth the risks? Curr Opin Nephrol Hypertens. 2012; 21(6): 600–6.
52. Huang SY, Chen YC, Kao YH, et al. Renal failure induces atrial arrhythmogenesis from discrepant electrophysiological remodeling and calcium regulation in pulmonary veins, sinoatrial node, and atria. Int J Cardiol. 2016; 1(202): 846-57.
Supplementary files
|
1. ATRIAL FIBRILLATION AND RENAL DYSFUNCTION: CURRENT STATE OF THE PROBLEM AND THE PROSPECTS OF FURTHER STUDY | |
| Subject | ||
| Type | титульный лист | |
Download
(31KB)
|
Indexing metadata ▾ | |
|
2. Неозаглавлен | |
| Subject | ||
| Type | Исследовательские инструменты | |
Download
(345KB)
|
Indexing metadata ▾ | |
|
|
3. Неозаглавлен | |
| Subject | ||
| Type | Исследовательские инструменты | |
Download
(227KB)
|
Indexing metadata ▾ | |
|
|
4. ATRIAL FIBRILLATION AND RENAL DYSFUNCTION: CURRENT STATE OF THE PROBLEM AND THE PROSPECTS OF FURTHER STUDY | |
| Subject | ||
| Type | Исследовательские инструменты | |
Download
(24KB)
|
Indexing metadata ▾ | |
Review
For citations:
Protasov K.V., Dorzhieva V.Z., Petuhova E.A. ATRIAL FIBRILLATION AND RENAL DYSFUNCTION: CURRENT STATE OF THE PROBLEM AND THE PROSPECTS OF FURTHER STUDY. Russian Journal of Cardiology. 2016;(4-eng):198-201. https://doi.org/10.15829/1560-4071-2016-4-eng-198-201
Views:
917
Email this article 